Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients

Therapeutic Drug Monitoring

Volumn 22, Issue 5, 2000, Pages 522-531

  Wrishko, Rebecca E ^a,b   Levine, Marc ^a,b   Khoo, Dominique ^b   Abbott, Phyllis ^b   Hamilton, Don ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Bayesian estimation; NONMEM modeling; Pediatric pharmacokinetics; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; FEMALE; HUMAN; INFUSION PUMP; MALE; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG MONITORING; FEMALE; HUMANS; MALE; VANCOMYCIN;

EID: 0033806739     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200010000-00004     Document Type: Article

References (38)

1. Pharmacokinetics of dosing regimens which use multiple intravenous infusions: Gentamicin in burn patients
2. Vancomycin: A review
3. Vancomycin pharmacokinetics in infants: Relationships to indices of maturation
4. Vancomycin pharmacokinetics and dose recommendations for preterm infants
5. The clinical pharmacology of vancomycin in seriously ill preterm infants
6. Vancomycin pharmacokinetics in very low birth weight neonates
7. Vancomycin pharmacokinetics in neonates and infants: A retrospective evaluation
8. Vancomycin pharmacokinetics and dosing in premature neonates
9. Vancomycin pharmacokinetics in premature infants
10. Vancomycin pharmacokinetics in small, seriously ill infants
11. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants
12. Vancomycin pharmacokinetics in infants: Relationships to postconceptional age and serum creatinine
13. Changes in vancomycin pharmacokinetics in critically ill infants
14. Clinical pharmacology and efficacy of vancomycin in pediatric patients
15. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients
16. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children
17. Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients
18. Population pharmacokinetics of vancomycin in Japanese pediatric patients
19. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children
20. Pharmacokinetics of vancomycin: Observations in 28 patients and dosage recommendations
21. Vancomycin pharmacokinetics in patients with various degrees of renal function
22. Vancomycin pharmacokinetics
23. Vancomycin
24. Vancomycin
25. Routine monitoring of serum vancomycin concentrations: Can waiting be justified?
26. Clinical pharmacokinetics of vancomycin
27. Serum vancomycin concentrations: Reappraisal of their clinical value
28. Basic principles
29. Vancomycin
30. Some suggestions for measuring predictive performance
31. Pharmacokinetic optimisation of vancomycin therapy
32. Vancomycin therapeutic drug monitoring: Is it necessary?
33. Bayesian forecasting in pediatric populations
34. Why monitor peak vancomycin concentrations?
35. Special considerations for monitoring vancomycin concentrations in pediatric patients
36. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations
37. Bayesian forecasting of serum vancomycin concentrations with non-steady state sampling strategies
38. Vancomycin monitoring: One or two serum levels?